Medytox establishes US subsidiary Luvantas

Thomas Albright, former head of marketing strategy at Allegiant, is hired as the new CEO

Medytox establishes US subsidiary Luvantas
Yoo-Rim Kim 1
Jan 03, 2024 (Gmt+09:00) youforest@hankyung.com
Bio & Pharma

South Korean pharmaceutical company Medytox Inc. announced on Wednesday that its establishment of the US subsidiary Luvantas.

The goal is the global market entry of its non-animal-derived liquid toxin formulation MT10109L (ingredient name: NivobotulinumtoxinA)  for which it has applied for approval from the US Food and Drug Administration (FDA).

Medytox, holding 100% equity of Luvantas, established it in Irvine, California, to oversee local operations and marketing of the non-animal-derived liquid toxin formulation MT10109L in the US, Canada, and other regions.

Luvantas is also expected to venture into advanced country markets with products like hyaluronic acid filler Neuramis, derma cosmetic Neuraderm, and others in the future.

CEO of Luvantas Thomas Albright
CEO of Luvantas Thomas Albright

Thomas Albright, a former Allergan executive, has been recruited as the CEO of Luvantas. Known for successfully leading the global launch of Botox for aesthetic purposes, Albright has overseen the global marketing strategy for Botox and contributed to research and development in new therapeutic indications and next-generation biologics.

Medytox anticipates that Albright's expertise in the global skincare treatment market will lead to the successful US market entry of MT10109L with a goal for FDA approval by 2025.

Medytox submitted a biologics license application for MT10109L to the FDA on Dec. 27 last year.

MT10109L, a non-animal-derived liquid toxin formulation developed by Medytox, excludes the use of animal-derived components throughout the entire manufacturing process, including strain cultivation and raw material production.

Write to Yoo-Rim Kim at youforest@hankyung.com

Medytox to enter China’s botulinum toxin market with Newlux

Medytox to enter China’s botulinum toxin market with Newlux

South Korean pharmaceutical company Medytox Inc. on Tuesday announced its plan to enter the Chinese market for botulinum toxins (BTX) with its cutting-edge product Newlux developed by affiliate Numeco.Medytox will thus retract its application for imported drug registration for Meditoxin, who

Dubai delegation conducts due diligence on Medytox's plant in Korea

Dubai delegation conducts due diligence on Medytox's plant in Korea

DSP CEO Marwan Abdulaziz Janahi (second from left) at Medytox's Osong plant in South Korea(Courtesy of Medytox) South Korea's biopharmaceutical firm Medytox Inc. said on Monday that a high-level delegation led by Dubai Science Park (DSP) under Dubai's state-owned Tecom Group conducted due dilig

Korean court rules Daewoong poached Medytox’s botox strain

Korean court rules Daewoong poached Medytox’s botox strain

Korean botox maker Medytox A South Korean court on Friday ruled in favor of Medytox Inc. in a civil lawsuit against its crosstown rival Daewoong Pharmaceutical Co. over the source of its botulinum toxin, more commonly known as botox.The Seoul Central District Court accepted Medytox’s clai

Medytox to sell off 2.2 mn shares of Daewoong's American partner Evolus

Medytox to sell off 2.2 mn shares of Daewoong's American partner Evolus

Medytox headquarters in Seoul Medytox Inc. said in a regulatory filing on Wednesday that it is selling off approximately 2.19 million shares of Evolus, Daewoong Pharmaceutical's US partner, for 23.2 billion won ($18.5 million).Medytox has been the largest shareholder of Evolus, but once the dis

Medytox to build plant for finished toxin products in Dubai

Medytox  to build plant for finished toxin products in Dubai

Marwan Abdulaziz Janahi, CEO of Dubai Science Park(left) and Jung Hyunho, CEO of Medytox South Korea's biopharmaceutical company Medytox Inc. will build a plant for finished products containing botulinum toxin in the United Arab Emirates (UAE) in what will be the first such facility abroad cons